Literature DB >> 17999880

Combination antifungal therapy for the treatment of invasive yeast and mold infections.

John W Baddley1, Peter G Pappas.   

Abstract

Combination antifungal therapy has been an area of great research and clinical interest since antifungals became available decades ago, in part driven by the severe morbidity and mortality associated with invasive fungal infections. Because of the availability of newer antifungal agents including echinocandins and expanded-spectrum triazoles, interest in combination antifungal therapy for invasive mold disease, especially invasive aspergillosis, has grown. This review examines combination antifungal therapy for the treatment of yeast and molds, including current studies evaluating combination antifungal therapy in three clinically important invasive fungal infections: candidiasis, cryptococcosis, and aspergillosis. This article focuses on recent clinical data and potential future clinical directions.

Entities:  

Year:  2007        PMID: 17999880     DOI: 10.1007/s11908-007-0069-1

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  55 in total

1.  Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial.

Authors:  Annemarie E Brouwer; Adul Rajanuwong; Wirongrong Chierakul; George E Griffin; Robert A Larsen; Nicholas J White; Thomas S Harrison
Journal:  Lancet       Date:  2004-05-29       Impact factor: 79.321

2.  In-vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans.

Authors:  F Barchiesi; D Gallo; F Caselli; L F Di Francesco; D Arzeni; A Giacometti; G Scalise
Journal:  J Antimicrob Chemother       Date:  1999-07       Impact factor: 5.790

3.  Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.

Authors:  M S Saag; W G Powderly; G A Cloud; P Robinson; M H Grieco; P K Sharkey; S E Thompson; A M Sugar; C U Tuazon; J F Fisher
Journal:  N Engl J Med       Date:  1992-01-09       Impact factor: 91.245

4.  A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients.

Authors:  M Abele-Horn; A Kopp; U Sternberg; A Ohly; A Dauber; W Russwurm; W Büchinger; O Nagengast; P Emmerling
Journal:  Infection       Date:  1996 Nov-Dec       Impact factor: 3.553

5.  International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

Authors:  L Ostrosky-Zeichner; D Kontoyiannis; J Raffalli; K M Mullane; J Vazquez; E J Anaissie; J Lipton; P Jacobs; J H Jansen van Rensburg; J H Rex; W Lau; D Facklam; D N Buell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-10       Impact factor: 3.267

6.  A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group.

Authors:  M S Saag; G A Cloud; J R Graybill; J D Sobel; C U Tuazon; P C Johnson; W J Fessel; B L Moskovitz; B Wiesinger; D Cosmatos; L Riser; C Thomas; R Hafner; W E Dismukes
Journal:  Clin Infect Dis       Date:  1999-02       Impact factor: 9.079

7.  Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS.

Authors:  R A Larsen; S A Bozzette; B E Jones; D Haghighat; M A Leal; D Forthal; M Bauer; J G Tilles; J A McCutchan; J M Leedom
Journal:  Clin Infect Dis       Date:  1994-10       Impact factor: 9.079

8.  A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

Authors:  John H Rex; Peter G Pappas; Adolf W Karchmer; Jack Sobel; John E Edwards; Susan Hadley; Corstiaan Brass; Jose A Vazquez; Stanley W Chapman; Harold W Horowitz; Marcus Zervos; David McKinsey; Jeannette Lee; Timothy Babinchak; Robert W Bradsher; John D Cleary; David M Cohen; Larry Danziger; Mitchell Goldman; Jesse Goodman; Eileen Hilton; Newton E Hyslop; Daniel H Kett; Jon Lutz; Robert H Rubin; W Michael Scheld; Mindy Schuster; Bryan Simmons; David K Stein; Ronald G Washburn; Linda Mautner; Teng-Chiao Chu; Helene Panzer; Rebecca B Rosenstein; Jenia Booth
Journal:  Clin Infect Dis       Date:  2003-05-08       Impact factor: 9.079

9.  Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks.

Authors:  W E Dismukes; G Cloud; H A Gallis; T M Kerkering; G Medoff; P C Craven; L G Kaplowitz; J F Fisher; C R Gregg; C A Bowles; S Shadomy; A M Stamm; R B Diasio; L Kaufman; S Soong; W C Blackwelder
Journal:  N Engl J Med       Date:  1987-08-06       Impact factor: 91.245

10.  Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90.

Authors:  Ruth C Matthews; Gordon Rigg; Samantha Hodgetts; Tracey Carter; Caroline Chapman; Carl Gregory; Chris Illidge; James Burnie
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

View more
  5 in total

1.  Irreversible electropermeabilization of the human pathogen Candida albicans: an in-vitro experimental study.

Authors:  Vitalij Novickij; Audrius Grainys; Jurgita Svediene; Svetlana Markovskaja; Algimantas Paskevicius; Jurij Novickij
Journal:  Eur Biophys J       Date:  2014-11-09       Impact factor: 1.733

2.  Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  Lynne M Mofenson; Michael T Brady; Susie P Danner; Kenneth L Dominguez; Rohan Hazra; Edward Handelsman; Peter Havens; Steve Nesheim; Jennifer S Read; Leslie Serchuck; Russell Van Dyke
Journal:  MMWR Recomm Rep       Date:  2009-09-04

3.  Competitiveness during Dual-Species Biofilm Formation of Fusarium oxysporum and Candida albicans and a Novel Treatment Strategy.

Authors:  Annarita Falanga; Angela Maione; Alessandra La Pietra; Elisabetta de Alteriis; Stefania Vitale; Rosa Bellavita; Rosa Carotenuto; David Turrà; Stefania Galdiero; Emilia Galdiero; Marco Guida
Journal:  Pharmaceutics       Date:  2022-05-30       Impact factor: 6.525

4.  Sensitization of Candida albicans biofilms to various antifungal drugs by cyclosporine A.

Authors:  Ravikumar B Shinde; Nitin M Chauhan; Jayant S Raut; Sankunny M Karuppayil
Journal:  Ann Clin Microbiol Antimicrob       Date:  2012-10-04       Impact factor: 3.944

5.  Carum copticum and Thymus vulgaris oils inhibit virulence in Trichophyton rubrum and Aspergillus spp.

Authors:  Mohd Sajjad Ahmad Khan; Iqbal Ahmad; Swaranjit Singh Cameotra
Journal:  Braz J Microbiol       Date:  2014-08-29       Impact factor: 2.476

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.